Myelodysplastic syndrome

Paediatric myelodysplasia.
[9039731] Br Med Bull 52(4): 778-86 (1996)

Myelodysplastic syndromes: disease overview and therapy options.
[19093333] Manag Care 17(7 Suppl 6): 3-8 (2008)

Myelodysplastic syndromes: a practical approach to diagnosis and treatment.
[20048028] Cleve Clin J Med 77(1): 37-44 (2010)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.
[18472976] Ther Clin Risk Manag 3(4): 553-62 (2007)

Molecular mechanisms of myelodysplastic syndrome.
[12810828] Jpn J Clin Oncol 33(4): 153-60 (2003)

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
[17366593] Cancer 109(9): 1705-14 (2007)

Drug therapy for myelodysplastic syndrome: building evidence for action.
[16532501] Cancer 106(8): 1650-2 (2006)

Novel therapies for myelodysplastic syndromes.
[15241818] Cancer 101(2): 226-41 (2004)

The treatment of the myelodysplastic syndromes.
[10570410] Cancer 86(10): 1893-9 (1999)

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.
[18813208] Cancer Control 15 Suppl(-): 40-9 (2008)

Iron overload in myelodysplastic syndromes: diagnosis and management.
[20125080] Cancer Control 17 Suppl(-): 2-8 (2010)

Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.
[20010512] Cancer Control 16 Suppl(-): 2-10 (2009)

Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.
[18813207] Cancer Control 15 Suppl(-): 29-39 (2008)

Changing the treatment paradigm in myelodysplastic syndromes.
[18813206] Cancer Control 15 Suppl(-): 14-28 (2008)

Myelodysplastic syndromes: diagnosis and staging.
[18813205] Cancer Control 15 Suppl(-): 4-13 (2008)

Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
[17242662] Cancer Control 13 Suppl(-): 12-6 (2006)

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
[17242661] Cancer Control 13 Suppl(-): 4-11 (2006)

Classification, treatment goals, and management principles for myelodysplastic syndromes.
[15625530] Cancer Control 11(6 Suppl): 3-6 (2004)

Myelodysplastic syndromes in the elderly.
[11176039] Cancer Control 8(1): 79-102 (2001)

Differentiation therapy for myelodysplastic syndrome.
[11948096] Clin Cancer Res 8(4): 939-41 (2002)

Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis.
[17962620] Oncologist 12(10): 1264-73 (2007)

Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
[9009082] Leukemia 11(2): 206-11 (1997)

Iron chelation therapy in myelodysplastic syndromes.
[20672005] Adv Hematol 2010(-): 756289 (2010)

Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review.
[19705430] Am J Hematol 84(10): 671-7 (2009)

Update on the therapy for myelodysplastic syndrome.
[19195035] Am J Hematol 84(3): 177-86 (2009)

Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
[19037863] Am J Hematol 84(1): 3-5 (2009)

Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
[16044436] Am J Hematol 79(4): 329-31 (2005)

Neutrophilic panniculitis with myelodysplastic syndromes presenting as pustulosis: case report and review of the literature.
[15114599] Am J Hematol 76(1): 61-5 (2004)

Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management.
[10706766] Am J Hematol 63(4): 212-22 (2000)

Myelodysplastic syndromes.
[1519966] Arch Dis Child 67(7): 962-6 (1992)

Myeloproliferative disorders.
[18779404] Blood 112(6): 2190-8 (2008)

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
[18401028] Blood 112(2): 231-9 (2008)

Myelodysplastic syndromes.
[18467609] Blood 111(10): 4841-51 (2008)

Telomere maintenance and human bone marrow failure.
[18239083] Blood 111(9): 4446-55 (2008)

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
[17488875] Blood 110(4): 1092-7 (2007)

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
[16609072] Blood 108(2): 419-25 (2006)

Defective ribosome biogenesis in myelodysplastic syndromes.
[19794078] Haematologica 94(10): 1336-8 (2009)

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
[18838480] Haematologica 93(11): 1712-7 (2008)

Myelodysplastic/myeloproliferative disorders.
[18166777] Haematologica 93(1): 4-6 (2008)

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
[17145595] Haematologica 91(12): 1596-604 (2006)

European consensus on grading bone marrow fibrosis and assessment of cellularity.
[16079113] Haematologica 90(8): 1128-32 (2005)

Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
[9573680] Haematologica 83(3): 258-75 (1998)

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.
[9542325] Haematologica 83(1): 71-86 (1998)

The molecular basis of myelodysplastic syndromes.
[9175327] Haematologica 82(2): 191-204 (1997)

Myelodysplastic syndromes: the pediatric point of view.
[7672722] Haematologica 80(3): 268-79 (1995)

MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?
[19074057] Hematology Am Soc Hematol Educ Program -(-): 43-51 (2008)

Clinical issues in the management of patients with myelodysplasia.
[17124062] Hematology Am Soc Hematol Educ Program -(-): 205-10 (2006)

Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes.
[17124061] Hematology Am Soc Hematol Educ Program -(-): 199-204 (2006)

Immune pathology of myelodysplastic syndromes.
[11688840] Intern Med 40(10): 985-6 (2001)

Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.
[2999194] J Clin Pathol 38(11): 1201-17 (1985)

The myelodysplastic syndromes: diagnosis and treatment.
[16438486] Mayo Clin Proc 81(1): 104-30 (2006)

Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.
[15887439] Mayo Clin Proc 80(5): 681-98 (2005)

Myelodysplastic syndromes.
[2672599] West J Med 151(2): 161-7 (1989)

Focus on myeloproliferative diseases and myelodysplastic syndromes.
[15607959] Cancer Cell 6(6): 547-52 (2004)

An approach to dealing with mucosal damage.
[1999611] J Am Dent Assoc 122(2): 73-4 (1991)

Cytogenetic features in myelodysplastic syndromes.
[18414863] Ann Hematol 87(7): 515-26 (2008)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
[18265982] Ann Hematol 87(5): 345-52 (2008)

Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555069] Ann Oncol 21 Suppl 5(-): v158-61 (2010)

Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
[17210514] Am J Clin Pathol 127(2): 197-205 (2007)

Myelodysplastic/myeloproliferative neoplasms.
[19605822] Am J Clin Pathol 132(2): 281-9 (2009)

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
[12623843] Blood 102(1): 43-52 (2003)

Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
[12506028] Blood 101(9): 3386-90 (2003)

How I treat patients with myelodysplastic syndromes.
[19383969] Blood 113(25): 6296-303 (2009)

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
[19710499] Blood 114(26): 5251-5 (2009)

Myelodysplastic syndromes with bone marrow fibrosis.
[21282718] Haematologica 96(2): 180-3 (2011)

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
[21134982] Haematologica 96(3): 441-9 (2011)

Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
[21357714] Haematologica 96(3): 349-52 (2011)

Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome.
[21810969] Haematologica 96(8): 1081-3 (2011)

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
[19773261] Haematologica 95(2): 303-10 (2010)

The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.
[17550842] Haematologica 92(6): 723-7 (2007)

Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.
[19336747] Haematologica 94(4): 449-51 (2009)

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
[19546437] Haematologica 94(8): 1124-34 (2009)

Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.
[19644135] Haematologica 94(8): 1041-3 (2009)

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
[19850902] Haematologica 95(2): 340-2; author reply 343-4 (2010)

Childhood and adolescent lymphoid and myeloid leukemia.
[15561680] Hematology Am Soc Hematol Educ Program -(-): 118-45 (2004)

Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
[21239819] Hematology Am Soc Hematol Educ Program 2010(-): 357-62 (2010)

How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.
[21239812] Hematology Am Soc Hematol Educ Program 2010(-): 314-21 (2010)

Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
[21239814] Hematology Am Soc Hematol Educ Program 2010(-): 325-9 (2010)

Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
[19074076] Hematology Am Soc Hematol Educ Program -(-): 166-75 (2008)

Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
[19074059] Hematology Am Soc Hematol Educ Program -(-): 60-7 (2008)

The changing classification of myelodysplastic syndromes: what's in a name?
[20008250] Hematology Am Soc Hematol Educ Program -(-): 645-55 (2009)

Treatment of MDS: something old, something new, something borrowed...
[20008251] Hematology Am Soc Hematol Educ Program -(-): 656-63 (2009)

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
[20008252] Hematology Am Soc Hematol Educ Program -(-): 664-72 (2009)

New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?
[19112734] Blood Transfus 6(4): 191-8 (2008)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
[20507806] Health Technol Assess 14 Suppl 1(-): 69-74 (2010)

Managing myelodysplastic symptoms in elderly patients.
[19966910] Clin Interv Aging 4(-): 413-23 (2009)

Standards and impact of hematopathology in myelodysplastic syndromes (MDS).
[21317447] Oncotarget 1(7): 483-96 (2010)

Safety and efficacy of azacitidine in myelodysplastic syndromes.
[20957213] Drug Des Devel Ther 4(-): 221-9 (2010)

Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.
[21487529] Int J Clin Exp Pathol 4(3): 322-6 (2011)

Rational therapeutic options for patients with myeloproliferative neoplasms.
[21686205] Trans Am Clin Climatol Assoc 122(-): 11-26 (2011)

Therapy-related myelodysplastic syndrome: models and genetics.
[19857585] Biol Blood Marrow Transplant 16(1 Suppl): S45-7 (2010)

Iron overload in myelodysplastic syndromes.
[21082962] Expert Rev Hematol 2(3): 215-8 (2009)

Epigenetic changes in the myelodysplastic syndrome.
[20359628] Hematol Oncol Clin North Am 24(2): 317-30 (2010)

Mouse models of myelodysplastic syndromes.
[20359631] Hematol Oncol Clin North Am 24(2): 361-75 (2010)

Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.
[19327589] Hematol Oncol Clin North Am 23(2): 361-76 (2009)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
[20428194] Leukemia 24(6): 1128-38 (2010)

Management of myelodysplastic syndromes: 2008 update.
[19086598] Oncology (Williston Park) 22(12): 1344-52 (2008)

Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology.
[17220579] J Nihon Med Sch 73(6): 300-7 (2006)

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
[21189329] Cancer Res 71(3): 955-63 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Myelodysplastic syndrome.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Myelodysplastic syndrome.php on line 92